Delta variant doubles risk of COVID hospitalisation – Scottish study


2/2

© Reuters. FILE PHOTO: A person receives a dose of the Pfizer BioNTech vaccine at vaccination centre for those aged over 18 years old at the Belmont Health Centre in Harrow, amid the coronavirus disease (COVID-19) outbreak in London, Britain, June 6, 2021. REUTERS/H

2/2

LONDON (Reuters) – The Delta coronavirus variant doubles the risk of hospitalisation compared with the previously dominant variant in Britain, but two doses of vaccine still provide strong protection, a Scottish study found on Monday.

The study said early evidence suggested the protection from vaccines against the Delta variant, first identified in India, might be lower than the effectivessness against the Alpha variant, first identified in Kent, southeast England.

British Prime Minister Boris Johnson is expected to delay the ending of COVID-19 restrictions in England on Monday, following a rapid rise in cases of the Delta variant, which is also more transmissible than the Alpha variant.

The study, published in a research letter in the Lancet, looked at 19,543 community cases and 377 hospitalisations among 5.4 million people in Scotland, 7,723 cases and 1234 hospitalisations of which were found to have the Delta variant.

Chris Robertson, Professor of Public Health Epidemiology, University of Strathclyde, said that adjusting for age and comorbidities, the Delta variant roughly doubled the risk of hospitalisation, but vaccines still reduced that risk.

“If you test positive, then two doses of the vaccine or one dose for 28 days roughly reduces your risk of being admitted to hospital by 70%,” he told reporters.

See also  Global stocks lifted by Covid-19 lockdown relaxation measures – business live

Two weeks after the second dose, Pfizer (NYSE:) BioNTech’s vaccine was found to have 79% protection against infection from the Delta variant, compared to 92% against the Alpha variant. For Oxford-AstraZeneca’s vaccine, there was 60% protection against Delta compared with 73% for Alpha.

The researchers cautioned against using the data to compare the vaccines against each other due to differences in the cohorts which received each type of shot, and differences in how quickly immunity is developed with each shot.

They said two doses of vaccine provide much better protection than one dose against the Delta variant, and a delay to easing lockdown in England would help more people get second doses and for their immune responses to build up.

“I think any sort of increase in the window of opportunity before lockdown measures are completely brought to an end will be helpful,” said Aziz Sheikh, Director of the Usher Institute at the University of Edinburgh.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See also  Renishaw shares jump as founders look to sell up





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here